Business
Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update
Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company’s Lead Program into Clinical Trials BETHESDA, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments. “This has been a productive quarter for Gain, as we continued to demonstrate the broad reaching potential of our SEE-Tx platform,” said Eric Richman, Chief Executive Officer of Gain Therapeutics. “Our strategy of exploring previously unidentified allosteric binding sites and targeting them for therapeutic benefit has proved promising. Our STAR’s appear to correct enzyme misfolding, restore function and eliminate toxic substrate buildup, providing hope for patients suffering from neurodegenerative and lysosomal disorders. We are encouraged by recently presented data and look forward to the year ahead as we progress our programs in Parkinson’s and in Gaucher disease into the clinic.” Business and Recent Developments Presented positive pre-clinical data from its GBA Parkinson’s Disease (PD) program at the XXVII World Congress on Parkinson’s Disease and Related Disorders (IAPRD). In May, Gain presented data generated in two in vitro models and an in vivo model in a poster presentation titled “GT-02287, a Brain-Penetrant Structurally Targeted Allosteric Regulator for Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Models of Parkinson’s Disease.” The data showed the ability of lead compound GT-02287 to penetrate the brain, target and bind with the beta-glucocerebrosidase (GCase) protein, avoiding its degradation and allowing its transport to the lysosomes where the enzyme can carry out its biological function.Presented positive data on small molecule lead compound GBA1 in Parkinson’s Disease at the 2022 Synuclein Meeting. I...